➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Mallinckrodt
Moodys
Medtronic
Merck

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,802,142

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,802,142 protect, and when does it expire?

Patent 8,802,142 protects KEPPRA and is included in one NDA.

Protection for KEPPRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-six countries.

Summary for Patent: 8,802,142
Title:Pharmaceutical compositions comprising levetiracetam and process for their preparation
Abstract: The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation.
Inventor(s): Deleers; Michel (Linkebeek, BE), Hubert; Jean-Beno t (Haaltert, BE)
Assignee: UCB Pharma, S.A. (Brussels, BE)
Application Number:11/910,167
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Process;

Drugs Protected by US Patent 8,802,142

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-004 Jan 6, 2006 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-001 Nov 30, 1999 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-002 Nov 30, 1999 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-003 Nov 30, 1999 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,802,142

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05016189Jul 26, 2005
05016945Aug 4, 2005
PCT Information
PCT FiledJuly 24, 2006PCT Application Number:PCT/EP2006/007260
PCT Publication Date:February 01, 2007PCT Publication Number: WO2007/012439

International Family Members for US Patent 8,802,142

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 054581   Start Trial
Australia 2006274263   Start Trial
Brazil PI0606121   Start Trial
Canada 2581831   Start Trial
China 101068534   Start Trial
Cyprus 1115825   Start Trial
Denmark 1909764   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Baxter
Johnson and Johnson
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.